


## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the Application.

## LISTING OF CLAIMS

1-12. (cancelled).

13. (previously presented) A compound according Formula III,



or a pharmaceutically acceptable salt thereof, wherein:

R<sup>1a</sup> is selected from halogen, lower perfluoroalkyl, -NO<sub>2</sub>, and optionally substituted C<sub>1-4</sub>alkyl; and R<sup>1b</sup> is selected from halogen, -N(R<sup>5</sup>)R<sup>5</sup>, -SR<sup>5</sup>, perfluoroalkyl, and optionally substituted lower alkyl;

R<sup>3</sup> is independently selected from -H, halogen, trihalomethyl, -CN, -NO<sub>2</sub>, -OR<sup>5</sup>, -N(R<sup>5</sup>)OR<sup>5</sup>, -ON(R<sup>5</sup>)R<sup>5</sup>, -N(R<sup>5</sup>)N(R<sup>5</sup>)R<sup>5</sup>, -N(R<sup>5</sup>)R<sup>5</sup>, -S(O)<sub>0-2</sub>R<sup>5</sup>, -SO<sub>2</sub>N(R<sup>5</sup>)R<sup>5</sup>, -CO<sub>2</sub>R<sup>5</sup>, -C(O)N(R<sup>5</sup>)R<sup>5</sup>, -N(R<sup>5</sup>)SO<sub>2</sub>R<sup>5</sup>, -N(R<sup>5</sup>)C(O)R<sup>5</sup>, -N(R<sup>5</sup>)CO<sub>2</sub>R<sup>5</sup>, -C(O)R<sup>5</sup>, -C(=NR<sup>7</sup>)N(R<sup>5</sup>)R<sup>5</sup>, -C(=NR<sup>7</sup>)R<sup>5</sup>, -C(=NR<sup>7</sup>)OR<sup>5</sup>, -N(R<sup>5</sup>)C(=NR<sup>7</sup>)N(R<sup>5</sup>)R<sup>5</sup>, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl;

R<sup>5a</sup> is H;

each R<sup>5</sup> is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

two of R<sup>5</sup>, together with the atom or respective atoms to which they are attached, can combine to form an optionally substituted three- to seven-membered heterocyclic;

each R<sup>6</sup> is independently selected from -H, halogen, trihalomethyl, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -OR<sup>5</sup>, -N(R<sup>5</sup>)R<sup>5</sup>, -S(O)<sub>0-2</sub>R<sup>5</sup>, -SO<sub>2</sub>N(R<sup>5</sup>)R<sup>5</sup>, -CO<sub>2</sub>R<sup>5</sup>, -C(O)N(R<sup>5</sup>)R<sup>5</sup>, -N(R<sup>5</sup>)SO<sub>2</sub>R<sup>5</sup>, -N(R<sup>5</sup>)C(O)R<sup>5</sup>, -N(R<sup>5</sup>)CO<sub>2</sub>R<sup>5</sup>, -C(O)R<sup>5</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl; or

two of R<sup>6</sup>, together with the atom or atoms to which they are attached, can combine to form one of an optionally substituted three to seven-membered alicyclic, and an optionally substituted three to seven-membered heteroalicyclic;

each R<sup>7</sup> is independently selected from -H, -CN, -NO<sub>2</sub>, -N(R<sup>5</sup>)R<sup>5</sup>, -OR<sup>5</sup>, -S(O)<sub>0-2</sub>R<sup>5</sup>, -SO<sub>2</sub>N(R<sup>5</sup>)R<sup>5</sup>, -CO<sub>2</sub>R<sup>5</sup>, optionally substituted lower alkyl, optionally substituted lower alkenyl, and optionally substituted lower alkynyl; or

R<sup>5</sup> and R<sup>7</sup>, together with the atom or atoms to which they are attached, can combine to form a five- to seven-membered optionally substituted heterocyclyl;

each of X and Y is independently selected from -C(=O)-, -C(R<sup>6</sup>)R<sup>6</sup>-, -O-, -N(R<sup>5</sup>)-, -C(=NR<sup>7</sup>)-, and -S(O)<sub>0-2</sub>-; provided when X is -O- or -N(R<sup>5</sup>)-, then Y cannot contain phenyl, napthyl, cyclohexyl, dihydronaphthyl tetrahydronaphthyl, or a five- to six-membered heteroaryl, each optionally substituted; and

Q is either =N- or =C(H)-.

14. (previously presented) The compound according to claim 13, wherein R<sup>1a</sup> is selected from -NO<sub>2</sub>, halogen, perfluoroalkyl, haloalkyl, and optionally substituted C<sub>1-2</sub>alkyl.

15. (original) The compound according to claim 14, wherein R<sup>3</sup> is selected from optionally substituted -O-C<sub>1-4</sub>alkyl, -O-C<sub>1-4</sub>perfluoroalkyl, optionally substituted

-N(H)C<sub>1-4</sub>alkyl, optionally substituted -N(C<sub>1-4</sub>alkyl)C<sub>1-4</sub>alkyl, optionally substituted -S(O)<sub>0-2</sub>-C<sub>1-4</sub>alkyl, and optionally substituted -S(O)<sub>0-2</sub>-C<sub>1-4</sub>perfluoroalkyl.

16. (original) The compound according to claim 15, wherein Y is either -N(H)- or -C(R<sup>6</sup>)R<sup>6</sup>-.

17. (original) The compound according to claim 16, wherein X is selected from -O-, -N(R<sup>5</sup>)- and -S-.

18. (original) The compound according to claim 17, wherein Y is -C(R<sup>6</sup>)R<sup>6</sup>-; wherein each R<sup>6</sup> is independently selected from -H, halogen, trihalomethyl, -NH<sub>2</sub>, optionally substituted -O-C<sub>1-4</sub>alkyl, optionally substituted -N(H)C<sub>1-4</sub>alkyl, optionally substituted -S-C<sub>1-4</sub>alkyl, optionally substituted lower alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclylalkyl.

19. (original) The compound according to claim 18, wherein Y is -C(H)R<sup>6</sup>-; wherein R<sup>6</sup> is independently selected from -H, halogen, trihalomethyl, -NH<sub>2</sub>, optionally substituted -O-C<sub>1-4</sub>alkyl, optionally substituted -N(H)C<sub>1-4</sub>alkyl, optionally substituted -S-C<sub>1-4</sub>alkyl, optionally substituted lower alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclylalkyl.

20. (original) The compound according to claim 19, wherein Q is =C(H)-.

21-28. (cancelled)

29. (previously presented) The compound according to claim 13, wherein R<sup>1a</sup> is selected from halo, lower perfluoroalkyl, -NO<sub>2</sub>, and optionally substituted C<sub>1-4</sub>alkyl.

30-33. (Cancelled)

34. (previously presented) A compound selected from Table 3.

Table 3

Entry	Name	Structure
-------	------	-----------

**Table 3**

Entry	Name	Structure
1	2-[3-cyano-4,6-dimethyl-5-nitropyridin-2-yl)oxy]-N-[3-(trifluoromethyl)phenyl]acetamide	
5	N <sup>2</sup> -[2-amino-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide	
7	2-{{2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[3-(methyloxy)phenyl]acetamide	
9	2-{{2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-(4-chlorophenyl)acetamide	
11	2-{{2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-(3-chlorophenyl)acetamide	
14	2-{{2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]oxy}-N-[3-(trifluoromethyl)phenyl]acetamide	

Table 3

Entry	Name	Structure
16	2-{{2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-methyl-N-[3-(trifluoromethyl)phenyl]acetamide}	
17	N <sup>2</sup> -[4-amino-6-(methylthio)-1,3,5-triazin-2-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide	
20	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide	
30	2-amino-4-({2-[2,5-bis(methoxy)phenyl]-2-oxoethyl}thio)-6-(methylthio)pyrimidine-5-carbonitrile	
31	2-{{2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide}	
34	2-{{2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[4-chloro-3-(trifluoromethyl)phenyl]acetamide}	

Table 3

Entry	Name	Structure
35	2-amino-4-(methylthio)-6-({2-oxo-1-[3-(trifluoromethyl)phenyl]pyrrolidin-3-yl}thio)pyrimidine-5-carbonitrile	
36	2-{{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[6-(trifluoromethyl)pyridin-2-yl]acetamide}	
37	2-{{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[4-(trifluoromethyl)pyridin-2-yl]acetamide}	
41	2-{{[2-(acetylamino)-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide}	
42	(2S)-2-{{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]oxy}-N-[3-(trifluoromethyl)phenyl]propanamide}	
45	2-{{[2-amino-5-formyl-6-(methylamino)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide}	

Table 3

Entry	Name	Structure
46	2-{{2-amino-5-formyl-6-(methylthio)pyrimidin-4-yl}oxy}-N-[3-(trifluoromethyl)phenyl]acetamide	
47	2-{{4-amino-6-(methylthio)-1,3,5-triazin-2-yl}oxy}-N-[3-(trifluoromethyl)phenyl]acetamide	
54	2-{{2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl}thio}-N-[2-(methyoxy)-5-(trifluoromethyl)phenyl]acetamide	
55	2-{{2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl}thio}-N-[2-chloro-5-(trifluoromethyl)phenyl]acetamide	
58	N <sup>2</sup> -[2-amino-5-[(E)-hydrazonomethyl]-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide	

Table 3

Entry	Name	Structure
59	N <sup>2</sup> -[2-amino-5-[(E)-hydroxyimino)methyl]-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide	
60	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
61	2-{{[2-amino-5-cyano-6-(methylamino)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide	
62	2-{{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]thio}-N-[2-amino-5-(trifluoromethyl)phenyl]acetamide	
63	2-amino-4-(methylthio)-6-({{[6-(trifluoromethyl)-1H-benzimidazol-2-yl]methyl}thio)pyrimidine-5-carbonitrile	
64	2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]hydrazinecarboxamide	

Table 3

Entry	Name	Structure
65	N <sup>2</sup> -[5-cyano-2-(methylamino)-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide	
66	2-{[2-amino-5-cyano-6-(dimethylamino)pyrimidin-4-yl]thio}-N-[3-(trifluoromethyl)phenyl]acetamide	
67	(S)-1-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]prolinamide	
68	(2R)-2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]oxy}-N-[3-(trifluoromethyl)phenyl]propanamide	
69	1-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]oxy}-N-[3-(trifluoromethyl)phenyl]cyclopropane carboxamide	
70	(2S)-2-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]oxy}-3-methyl-N-[3-(trifluoromethyl)phenyl]butanamide	

**Table 3**

Entry	Name	Structure
72	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide	
73	1-{[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]amino}-N-[3-(trifluoromethyl)phenyl]cyclopropane carboxamide	
74	$N^2$ -[2-amino-5-cyano-6-(methylsulfinyl)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
75	$N^2$ -[2-amino-5-cyano-6-(methylsulfonyl)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
76	$N^2$ -(5-cyano-2-morpholin-4-ylpyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]glycinamide	
78	$N^2$ -[2-amino-5-cyano-6-(methoxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	

Table 3

Entry	Name	Structure
79	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[2-(methoxy)-5-(trifluoromethyl)phenyl]-L-alaninamide	
80	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[2-chloro-5-(trifluoromethyl)phenyl]-L-alaninamide	
83	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-D-alaninamide	
84	2-[(2-amino-5-cyano-6-morpholin-4-ylpyrimidin-4-yl)thio]-N-[3-(trifluoromethyl)phenyl]acetamide	
85	(R)-1-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]prolinamide	
86	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide	

Table 3

Entry	Name	Structure
87	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-[2-(dimethylamino)ethyl]-N-[3-(trifluoromethyl)phenyl]glycinamide	
88	$N^2$ -[2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
89	$N^2$ -(2,6-diamino-5-cyanopyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
90	$N^2$ -(2-amino-5-cyanopyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
91	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-methyl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
93	2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-1,2-dimethyl-N-[3-(trifluoromethyl)phenyl]hydrazinecarboxamide	

Table 3

Entry	Name	Structure
94	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-amino-5-(trifluoromethyl)phenyl]-L-alaninamide	
95	ethyl [1-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-2-({[3-(trifluoromethyl)phenyl]amino}carbo-nyl)hydrazino]acetate	
96	2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-2-methyl-N-[3-(trifluoromethyl)phenyl]hydrazinecarboxamide	
100	N <sup>2</sup> -[5-cyano-2-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]glycinamide	
101	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-(tetrahydro-2H-pyran-4-ylmethyl)-N-[3-(trifluoromethyl)phenyl]glycinamide	
102	N <sup>2</sup> -(2-amino-5-cyano-6-{[2-(dimethylamino)ethyl]oxy}pyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	

Table 3

Entry	Name	Structure
103	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-6-[(1-dimethylethyl)oxy]carbonyl]-N-[3-(trifluoromethyl)phenyl]-L-lysinamide	
104	2-amino-4-(methylthio)-6-(methyl{((1S)-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl}amino)pyrimidine-5-carbonitrile	
105	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-N-[3-(trifluoromethyl)phenyl]glycinamide	
106	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-{[2-(diethylamino)ethyl]amino}-5-(trifluoromethyl)phenyl]-L-alaninamide	
107	2-amino-4-(methylthio)-6-((1S)-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl)amino)pyrimidine-5-carbonitrile	

Table 3

Entry	Name	Structure
108	2-{2-amino-5-cyano-6-[1-(3-trifluoromethyl-phenylcarbamoyl)-1S-ethylamino]-pyrimidin-4-ylamino}-N-(3-trifluoromethyl-phenyl)-2S-propionamide	
109	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-methyl-N-(3-methylphenyl)glycinamide	
110	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-2-methyl-N-[3-(1-methylethyl)phenyl]glycinamide	
111	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-5-[imino(nitroamino)methyl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide	
112	methyl 3-((N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-L-alanyl)amino)-5-(trifluoromethyl)benzoate	
113	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-(3-nitrophenyl)-L-alaninamide	

Table 3

Entry	Name	Structure
114	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-lysinamide	
115	$N^2$ -[2-amino-5-cyano-6-(propyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
117	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-argininamide	
118	$N^2$ -[2-amino-5-cyano-6-(methylsulfinyl)pyrimidin-4-yl]-N-2-methyl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
119	$N^2$ -[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]-N-2-methyl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
120	$N^2$ -[2-amino-5-cyano-6-(propyloxy)pyrimidin-4-yl]-N-2-methyl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	

Table 3

Entry	Name	Structure
121	$N^2$ -[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-2-methyl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
122	$N^2$ -{2-amino-5-cyano-6-[(1-methylethyl)oxy]pyrimidin-4-yl}-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
123	N-5-acetyl-N-2-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide	
124	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-(3-aminophenyl)-L-alaninamide	
125	3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-L-alanyl}amino)-N-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)benzamide	
126	2-(methyloxy)ethyl ((4S)-4-[[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]amino]-5-oxo-5-[(3-(trifluoromethyl)phenyl)amino]pentyl)carbamate	

Table 3

Entry	Name	Structure
127	2-[2-amino-5-cyano-6-(ethyoxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]hydrazinecarboxamide	
128	1,1-dimethylethyl ((4S)-4-{[2-amino-5-cyano-6-(ethyoxy)pyrimidin-4-yl]amino}-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)carbamate	
130	3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-methyl-L-alanyl}amino)-N-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)benzamide	
131	3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-methyl-L-alanyl}amino)-N-[3-(4-methylpiperazin-1-yl)propyl]-5-(trifluoromethyl)benzamide	

Table 3

Entry	Name	Structure
132	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~2~-methyl-N-{3-[(trifluoromethyl)oxy]phenyl}-L-alaninamide	<p style="text-align: right;">Chiral</p>
133	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-(3-bromophenyl)-N~2~-methyl-L-alaninamide	<p style="text-align: right;">Chiral</p>
134	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-{2-[(dimethylamino)ethyl]oxy}-5-[(trifluoromethyl)oxy]phenyl)-N~2~-methyl-L-alaninamide	<p style="text-align: right;">Chiral</p>
135	3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-methyl-L-alanyl}amino)-N-(2-morpholin-4-ylethyl)-5-(trifluoromethyl)benzamide	<p style="text-align: right;">Chiral</p>

Table 3






Entry	Name	Structure
136	$N^2$ -[2-amino-5-cyano-6-(ethyoxy)pyrimidin-4-yl]-N~2~-methyl-N-[3-(trifluoromethyl)phenyl]-L-lysinamide	
137	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-[(2-(dimethylamino)ethyl)oxy]-5-(trifluoromethyl)phenyl]-L-alaninamide	
138	(2S)-2-[(2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl)amino]-3-oxo-3-[(3-(trifluoromethyl)phenyl)amino]propyl acetate	
139	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~1~-[3-(trifluoromethyl)phenyl]-L-glutamamide	
140	2-[2-amino-5-cyano-6-(methyoxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]hydrazinecarboxamide	

Table 3

Entry	Name	Structure
141	3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-L-alanyl}amino)-N-hydroxy-5-(trifluoromethyl)benzamide	
142	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-3-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	
143	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-5-morpholin-4-yl-N-[3-(trifluoromethyl)phenyl]-L-norvalinamide	
144	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-5-[2-(methyoxyethyl)-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide	
145	3-({N-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-L-alanyl}amino)-5-(trifluoromethyl)benzoic acid	

Table 3

Entry	Name	Structure
146	methyl N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alpha-glutamate	
147	N <sup>5</sup> -(aminocarbonyl)-N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide	
148	N <sup>2</sup> -[2-amino-5-cyano-6-(ethyoxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide	
149	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alpha-glutamine	
150	N <sup>2</sup> -[2-amino-5-cyano-6-(ethyoxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-serinamide	

Table 3





Entry	Name	Structure
151	$N^2$ -[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-O-(phenylmethyl)-N-[3-(trifluoromethyl)phenyl]-L-serinamide	
152	$N^2$ -[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-argininamide	
153	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~2~-methyl-N <sup>6</sup> -{[(phenylmethyl)oxy]carbonyl}-N-[3-(trifluoromethyl)phenyl]-L-lysinamide	
154	N- $\alpha$ -[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-tyrosinamide	

Table 3

Entry	Name	Structure
155	$N^5$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide	
156	$N^2$ -[2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl]-N-6-,N-6-dimethyl-N-[3-(trifluoromethyl)phenyl]-L-lysinamide	
157	$N^2$ -[2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl]-N-[3-[(4-methylpiperazin-1-yl)carbonyl]-5-(trifluoromethyl)phenyl]-L-alaninamide	
158	3-({N-[2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl]-L-alanyl}amino)-N-(3-pyrrolidin-1-ylpropyl)-5-(trifluoromethyl)benzamide	

Table 3




Entry	Name	Structure
159	3-({N-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-L-alanyl}amino)-N-(2-morpholin-4-ylethyl)-5-(trifluoromethyl)benzamide	 <p>Chiral</p>
160	3-({N-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-L-alanyl}amino)-N-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)benzamide	 <p>Chiral</p>
161	3-({N-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-L-alanyl}amino)-N-[3-(4-methylpiperazin-1-yl)propyl]-5-(trifluoromethyl)benzamide	 <p>Chiral</p>

Table 3

Entry	Name	Structure
162	<chem>N^2-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N^2~-methyl-N^6-{[(phenylmethyl)oxy]carbonyl}-N-[3-(trifluoromethyl)phenyl]-L-lysinamide</chem>	
163	<chem>1,1-dimethylethyl ((4S)-4-{[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]amino}-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)carbamate</chem>	
164	<chem>(2S)-2-{[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]amino}-3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl acetate</chem>	
165	<chem>phenylmethyl N^2~-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alpha-glutamate</chem>	

Table 3

Entry	Name	Structure
166	N <sup>2</sup> , N <sup>5</sup> -diacetyl-N-2~-[2-(acetylamino)-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide	<p style="text-align: right;">Chiral</p>
167	2-(methoxyethyl)((4S)-4-((2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl)amino)-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)carbamate	<p style="text-align: right;">Chiral</p>
168	N <sup>2</sup> -[2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl]-5-morpholin-4-yl-N-[3-(trifluoromethyl)phenyl]-L-norvalinamide	<p style="text-align: right;">Chiral</p>
169	N-((4S)-4-((2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl)amino)-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)-N,N-dimethylmethanaminium	<p style="text-align: right;">Chiral</p>
170	Methyl N <sup>2</sup> -[2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alpha-glutamate	<p style="text-align: right;">Chiral</p>

Table 3






Entry	Name	Structure
171	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~6~,N~6~-dimethyl-N-[3-(trifluoromethyl)phenyl]-L-lysinamide	 Chiral
172	$N^2$ -[2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl]-N~2~-methyl-N-[3-(trifluoromethyl)oxy]phenyl]-L-alaninamide	 Chiral
173	$N^2$ -[2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alpha-glutamine	 Chiral
174	$N\sim2\sim$ -[2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl]-N-(3-bromophenyl)-N~2~-methyl-L-alaninamide	 Chiral
175	$N^2$ -[2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl]-N <sup>1</sup> -[3-(trifluoromethyl)phenyl]-L-glutamamide	 Chiral

Table 3

Entry	Name	Structure
176	$N^2$ -[2-amino-5-cyano-6-(ethyoxy)pyrimidin-4-yl]-3-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	<p style="text-align: right;">Chiral</p>
177	2-(2-amino-5-cyano-6-ethoxypyrimidin-4-ylamino)-5-hydrazinyl-5-oxo-N-(3-(trifluoromethyl)phenyl)pentanamide	<p style="text-align: right;">Chiral</p>
178	$N^2$ -[2-amino-5-cyano-6-(methyoxy)pyrimidin-4-yl]-3-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	<p style="text-align: right;">Chiral</p>
179	$N^2$ -[2-amino-5-cyano-6-(methyoxy)pyrimidin-4-yl]-N-[3-{[2-(dimethylamino)ethyl]oxy}-5-(trifluoromethyl)phenyl]-L-alaninamide	<p style="text-align: right;">Chiral</p>
180	$N^2$ -[2-amino-5-cyano-6-(ethyoxy)pyrimidin-4-yl]-N-[3-{[2-(dimethylamino)ethyl]oxy}-5-(trifluoromethyl)phenyl]-L-alaninamide	<p style="text-align: right;">Chiral</p>

Table 3

Entry	Name	Structure
181	$N^2$ -[2-amino-5-cyano-6-(methyoxy)pyrimidin-4-yl]-N-(3-bromophenyl)- $N^2$ -methyl-L-alaninamide	<p style="text-align: right;">Chiral</p>
182	phenylmethyl $N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-alpha-glutamate	<p style="text-align: right;">Chiral</p>
183	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-O-(phenylmethyl)-N-[3-(trifluoromethyl)phenyl]-L-serinamide	<p style="text-align: right;">Chiral</p>
184	$N^2$ -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~5~,N~5~-bis[2-(methyoxy)ethyl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide	<p style="text-align: right;">Chiral</p>
185	1,1-dimethylethyl ((4S)-4-{[2-amino-5-cyano-6-(methyoxy)pyrimidin-4-yl]amino}-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)carbamate	<p style="text-align: right;">Chiral</p>

Table 3

Entry	Name	Structure
186	N <sup>5</sup> -acetyl- N <sup>2</sup> -[2-amino-5-cyano-6-(ethyoxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide	<p style="text-align: right;">Chiral</p>
187	N <sup>5</sup> -acetyl- N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide	<p style="text-align: right;">Chiral</p>
188	N <sup>2</sup> -[2-amino-5-cyano-6-(methyoxy)pyrimidin-4-yl]- N <sup>2</sup> -methyl-N-{3-[{(trifluoromethyl)oxy]phenyl}-L-alaninamide	
189	methyl 3-({N-[2-amino-5-cyano-6-(methyoxy)pyrimidin-4-yl]-L-alanyl}amino)-5-(trifluoromethyl)benzoate	

Table 3

Entry	Name	Structure
190	3-( <i>{N</i> -[2-amino-5-cyano-6-(methyoxy)pyrimidin-4-yl]-L-alanyl}amino)- <i>N</i> -[2-(dimethylamino)ethyl]-5-(trifluoromethyl)benzamide	<p style="text-align: right;">Chiral</p>
191	<i>N</i> <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-3-morpholin-4-yl- <i>N</i> -[3-(trifluoromethyl)phenyl]-L-alaninamide	<p style="text-align: right;">Chiral</p>
192	<i>N</i> <sup>2</sup> -[2-amino-5-cyano-6-(methyoxy)pyrimidin-4-yl]-3-morpholin-4-yl- <i>N</i> -[3-(trifluoromethyl)phenyl]-L-alaninamide	<p style="text-align: right;">Chiral</p>
193	<i>N</i> <sup>2</sup> -[2-amino-5-cyano-6-(ethyoxy)pyrimidin-4-yl]-3-morpholin-4-yl- <i>N</i> -[3-(trifluoromethyl)phenyl]-L-alaninamide	<p style="text-align: right;">Chiral</p>
194	<i>N</i> <sup>5</sup> -(aminocarbonyl)- <i>N</i> <sup>2</sup> -[2-amino-5-cyano-6-(ethyoxy)pyrimidin-4-yl]- <i>N</i> -[3-(trifluoromethyl)phenyl]-L-ornithinamide	<p style="text-align: right;">Chiral</p>

Table 3

Entry	Name	Structure
195	N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-D-lysinamide	<p style="text-align: right;">Chiral</p>
196	N <sup>2</sup> -[2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-D-lysinamide	<p style="text-align: right;">Chiral</p>
197	N <sup>2</sup> -[2-amino-5-cyano-6-(ethoxy)pyrimidin-4-yl]-O-methyl-N-[3-(trifluoromethyl)phenyl]-L-serinamide	<p style="text-align: right;">Chiral</p>
198	N <sup>2</sup> -[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N~5~-(methylsulfonyl)-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide	<p style="text-align: right;">Chiral</p>

35. (previously presented) A pharmaceutical composition comprising the compound according to claims 13 and a pharmaceutically acceptable carrier.

36. (previously presented) A metabolite of the compound or the pharmaceutical composition according to claims 13.

37. (previously presented) A method of modulating *in vivo* activity of a kinase, the method comprising administering to a subject an effective amount of a composition comprising a compound according to claim 13.
38. (original) The method according to claim 37, wherein the kinase is p70S6K.
39. (original) The method according to claim 38; wherein modulating the *in vivo* activity of p70S6K comprises inhibition of p70S6K.
40. (previously presented) A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of a composition comprising a compound according to claim 13.
41. (previously presented) A method of screening for modulator of a p70S6 kinase, the method comprising combining either a compound according to claim 13, and at least one candidate agent and determining the effect of the candidate agent on the activity of said kinase.
42. (previously presented) A method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of: the compound according to claims 13.
43. (currently amended) A method of inhibiting abnormal metabolic activity in a cell, the method comprising administering an effective amount of: the compound according to any of claim 13.